Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotics + pyridoxine
- Development stage
- Unknown
- Lead developer
- The Third Xiangya Hospital of Central South University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probiotics + pyridoxine is a combination therapy consisting of a multi-strain probiotic mixture (typically including *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*) and pyridoxine (Vitamin B6). Developed by researchers at The Third Xiangya Hospital of Central South University, this combination is primarily investigated for the prevention and mitigation of postoperative neurocognitive impairment (POCI) in elderly patients. The therapeutic rationale is based on the modulation of the gut-microbiota-brain axis. Probiotics work to restore intestinal microbial balance, strengthen the gut barrier, and reduce systemic and neuroinflammation. Pyridoxine serves as an essential cofactor for enzymes involved in the synthesis of key neurotransmitters, such as GABA, dopamine, and serotonin, and plays a critical role in homocysteine metabolism, which is linked to cognitive health and neuroprotection.
- Other names
- Probiotics and Vitamin B6Probiotics and Pyridoxine
02
Targets
PDXK (Pyridoxal kinase)
Beyond the preview
Go deeper on probiotics + pyridoxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotics + pyridoxine.